Key clinical point: Preoperative nivolumab, with or without ipilimumab, appears safe and effective in patients with oral cavity squamous cell carcinoma.
Major finding: Volumetric responses occurred in 50% of patients in the nivolumab monotherapy arm and 53% of those in the nivolumab-ipilimumab arm. There were three severe immune-related adverse events, and two of these were reversible.
Study details: Phase 2 trial of 29 evaluable patients with oral cavity squamous cell carcinoma.
Disclosures: Bristol-Myers Squibb funded the study. Dr. Schoenfeld disclosed relationships with Bristol-Myers Squibb and other companies.
Schoenfeld J et al. HNCS 2020. Abstract 1.